The United States has emerged as the global epicenter for the GLP-1 weight-loss drug boom, driving a significant revenue surge for Novo Nordisk's obesity franchise. The company's revenue from weight-management treatments skyrocketed from $1.3 billion in 2021 to approximately $12.4 billion by 2025. Currently, the US market accounts for more than 60% of global revenue for drugs specifically marketed for weight loss. While Wegovy remains the primary driver of this growth, Ozempic is frequently utilized off-label for weight loss purposes. This concentration highlights the pharmaceutical industry's heavy reliance on robust US demand and high obesity prevalence. Analysts maintain a bullish outlook for major players like Novo Nordisk and Eli Lilly as they continue to capitalize on this rapidly expanding therapeutic segment.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis